G1 Therapeutics
G1 Therapeutics - Innovations in Oncology.
Market cap
$377m
Enterprise value
$364m
Share price
$7.15 GTHX
loading funding rounds…
Franklin Templeton Investments(exited)
Cowen Group(exited)
Cormorant Asset Management(exited)
Eshelman Ventures(exited)
Aju IB Investment(exited)
Hatteras Venture Partners(exited)
Rock Springs Capital(exited)
MedImmune Ventures(exited)
RA Capital Management(exited)
Lumira Ventures(exited)
Hercules Capital(exited)
Solasta Ventures(exited)
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | (30 %) | 63 % | 61 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (119 %) | (166 %) | - | (212 %) | (454 %) | (263 %) | (42 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (117 %) | (166 %) | - | (219 %) | (471 %) | (288 %) | (58 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 105 % | 138 % | - | 162 % | 242 % | 162 % | 53 % |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.